Risk factors

Bakkt added substantial new risk disclosures regarding its Bitcoin investment policy, international expansion in Asia, and heavy revenue concentration risks.

Burlington highlighted increased scrutiny over ESG goals, immigration enforcement impacts on Hispanic shoppers, AI cybersecurity risks, and updated debt figures.

Columbus Acquisition Corp focuses on completing a business combination, managing extension fees, and handling unit conversions and share exchanges.

Sprinklr added tax and share repurchase risks while expanding disclosures on AI agentic systems and geopolitical conflicts.

The company completed the acquisition of Pre-Acquisition Damora in November 2025 and shifted its pipeline focus to lead asset DMR-001 targeting mutCALR-driven MPNs. As a preclinical-stage biotech, operations are funded by $257.6 million in cash expected to last into Phase 3 development.

DarioHealth faces severe liquidity pressure, highlighted by $452M in accumulated deficits, a $50M Callodine loan facility, and a strategic review process.

Pending merger with FullBeauty introduces significant transaction and integration uncertainties for the company.

Integration of the NURO acquisition and its Quell platform brings new commercialization, app-security, and FTC compliance risks.

Eledon added risks concerning massive share dilution from recent private placements and offerings, alongside patent portfolio maintenance challenges. The company continues to face capital raises, regulatory uncertainties under the Inflation Reduction Act, and clinical-stage manufacturing hurdles.

New disclosures detail growing risks from the Inflation Reduction Act, government price reporting, and supply chain tracking.

The company replaced its broad ESG risk factor with a specific corporate responsibility risk highlighting retail sourcing and materials. Inflation language was updated to remove specific 2022 references in favor of general historical levels.

Genelux is advancing its lead immunotherapy candidate, Olvi-Vec, while managing ongoing clinical trials and capital needs.